2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
18
Sarcoma
17
Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Brain Neoplasms
5
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Leiomyosarcoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Advanced Breast Cancer
2
Interventions
Cyclophosphamide
447
Rituximab
406
Etoposide
225
Vincristine
217
Doxorubicin
204
Filgrastim
201
Prednisone
178
Cytarabine
160
Radiotherapy
152
fludarabine phosphate
148
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
130
Melphalan
128
fludarabine
116
Busulfan
101
Dexamethasone
93
Tacrolimus
76
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
72
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
63
Bendamustine Hydrochloride
63
Lenalidomide
62
Cyclosporine
62
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma
×
eribulin
×
Clear all
NCT02082626
2020-03-10
ERIBULIN
University of Oklahoma
Phase 1
Terminated
3 enrolled
NCT02171260
2019-01-15
BOLD 113
Eisai Inc.
Phase 1
Completed
23 enrolled
22 charts